Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches
Abstract Lennox–Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug‐resistant seizures (which must include tonic seizures) with classical onset before 8 years (although some cases with later onset have also been described), abno...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Epilepsia Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/epi4.13075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206500276043776 |
|---|---|
| author | Stéphane Auvin Alexis Arzimanoglou Mercè Falip Pasquale Striano J. Helen Cross |
| author_facet | Stéphane Auvin Alexis Arzimanoglou Mercè Falip Pasquale Striano J. Helen Cross |
| author_sort | Stéphane Auvin |
| collection | DOAJ |
| description | Abstract Lennox–Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug‐resistant seizures (which must include tonic seizures) with classical onset before 8 years (although some cases with later onset have also been described), abnormal electroencephalographic features, and cognitive and behavioral impairments. Management and treatment of LGS are challenging, due to associated comorbidities and the treatment resistance of seizures. A panel of five epileptologists reconvened to provide updated guidance and treatment algorithms for LGS, incorporating recent advancements in antiseizure medications (ASMs) and understanding of DEEs. The resulting consensus document is based on current evidence from clinical trials and clinical practice and the panel's expert opinion, focusing on new ASMs with novel mechanisms of action, such as highly purified cannabidiol and fenfluramine. For a patient presenting with newly diagnosed LGS or suspected LGS, the recommended first‐line treatment continues to be valproate. If this is ineffective as monotherapy, adjunctive therapy with, firstly, lamotrigine and secondly, rufinamide, is recommended. If seizure control remains suboptimal, subsequent adjunctive ASM treatment options include (alphabetically) cannabidiol, clobazam, felbamate, fenfluramine, and topiramate, although evidence for these is more limited. Whenever possible, no more than two ASMs should be used together. Nonpharmacological treatment approaches should be used in conjunction with ASM therapy and include ketogenic diet therapies, vagus nerve stimulation, and corpus callosotomy. Patients with LGS that has evolved from another type of epilepsy who are not already being treated with valproate should be transitioned to valproate and then managed using the same algorithm as for newly diagnosed LGS. Older patients with established LGS should be reviewed at least annually by a suitably experienced neurologist. The revised guidance aims to improve seizure control and quality of life for patients with LGS through personalized, evidence‐based treatment strategies while addressing the challenges of accurate diagnosis and management in a rapidly evolving therapeutic landscape. Plain Language Summary Lennox–Gastaut syndrome (LGS) is a severe type of epilepsy that usually starts in childhood but continues into adulthood. It is characterized by a variety of different types of seizures (abnormal electrical activity in the brain), which are difficult to treat and often cause people with the condition to fall and injure themselves. Most people with LGS have learning difficulties and need a lot of support, often in residential care. The authors are experts in treating people with LGS and this article provides up‐to‐date guidance and advice on how best to care for those with the condition. |
| format | Article |
| id | doaj-art-a656f775b1134aceb48421b18d74a342 |
| institution | Kabale University |
| issn | 2470-9239 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Epilepsia Open |
| spelling | doaj-art-a656f775b1134aceb48421b18d74a3422025-02-07T09:12:45ZengWileyEpilepsia Open2470-92392025-02-011018510610.1002/epi4.13075Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approachesStéphane Auvin0Alexis Arzimanoglou1Mercè Falip2Pasquale Striano3J. Helen Cross4INSERM NeuroDiderot Université Paris Cité Paris FranceEpilepsy Unit, Child Neurology Department, Hospital San Juan de Déu Coordinator of the ERN EpiCARE Universitat de Barcelona Barcelona SpainEpilepsy Unit, Neurology Service Bellvitge University Hospital, L'Hospitalet de Llobregat Barcelona SpainDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health University of Genoa Genoa ItalyUCL NIHR BRC Great Ormond Street Institute of Child Health London UKAbstract Lennox–Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug‐resistant seizures (which must include tonic seizures) with classical onset before 8 years (although some cases with later onset have also been described), abnormal electroencephalographic features, and cognitive and behavioral impairments. Management and treatment of LGS are challenging, due to associated comorbidities and the treatment resistance of seizures. A panel of five epileptologists reconvened to provide updated guidance and treatment algorithms for LGS, incorporating recent advancements in antiseizure medications (ASMs) and understanding of DEEs. The resulting consensus document is based on current evidence from clinical trials and clinical practice and the panel's expert opinion, focusing on new ASMs with novel mechanisms of action, such as highly purified cannabidiol and fenfluramine. For a patient presenting with newly diagnosed LGS or suspected LGS, the recommended first‐line treatment continues to be valproate. If this is ineffective as monotherapy, adjunctive therapy with, firstly, lamotrigine and secondly, rufinamide, is recommended. If seizure control remains suboptimal, subsequent adjunctive ASM treatment options include (alphabetically) cannabidiol, clobazam, felbamate, fenfluramine, and topiramate, although evidence for these is more limited. Whenever possible, no more than two ASMs should be used together. Nonpharmacological treatment approaches should be used in conjunction with ASM therapy and include ketogenic diet therapies, vagus nerve stimulation, and corpus callosotomy. Patients with LGS that has evolved from another type of epilepsy who are not already being treated with valproate should be transitioned to valproate and then managed using the same algorithm as for newly diagnosed LGS. Older patients with established LGS should be reviewed at least annually by a suitably experienced neurologist. The revised guidance aims to improve seizure control and quality of life for patients with LGS through personalized, evidence‐based treatment strategies while addressing the challenges of accurate diagnosis and management in a rapidly evolving therapeutic landscape. Plain Language Summary Lennox–Gastaut syndrome (LGS) is a severe type of epilepsy that usually starts in childhood but continues into adulthood. It is characterized by a variety of different types of seizures (abnormal electrical activity in the brain), which are difficult to treat and often cause people with the condition to fall and injure themselves. Most people with LGS have learning difficulties and need a lot of support, often in residential care. The authors are experts in treating people with LGS and this article provides up‐to‐date guidance and advice on how best to care for those with the condition.https://doi.org/10.1002/epi4.13075antiseizure medicationsdevelopmental and epileptic encephalopathyepilepsytherapy algorithmupdate |
| spellingShingle | Stéphane Auvin Alexis Arzimanoglou Mercè Falip Pasquale Striano J. Helen Cross Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches Epilepsia Open antiseizure medications developmental and epileptic encephalopathy epilepsy therapy algorithm update |
| title | Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches |
| title_full | Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches |
| title_fullStr | Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches |
| title_full_unstemmed | Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches |
| title_short | Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches |
| title_sort | refining management strategies for lennox gastaut syndrome updated algorithms and practical approaches |
| topic | antiseizure medications developmental and epileptic encephalopathy epilepsy therapy algorithm update |
| url | https://doi.org/10.1002/epi4.13075 |
| work_keys_str_mv | AT stephaneauvin refiningmanagementstrategiesforlennoxgastautsyndromeupdatedalgorithmsandpracticalapproaches AT alexisarzimanoglou refiningmanagementstrategiesforlennoxgastautsyndromeupdatedalgorithmsandpracticalapproaches AT mercefalip refiningmanagementstrategiesforlennoxgastautsyndromeupdatedalgorithmsandpracticalapproaches AT pasqualestriano refiningmanagementstrategiesforlennoxgastautsyndromeupdatedalgorithmsandpracticalapproaches AT jhelencross refiningmanagementstrategiesforlennoxgastautsyndromeupdatedalgorithmsandpracticalapproaches |